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Despite significant progress achieved in transplantation, immunosuppressive therapies
currently used to prevent graft rejection are still endowedwith severe side effects impairing
their efficiency over the long term. Thus, the development of graft-specific, non-toxic
innovative therapeutic strategies has become a major challenge, the goal being to
selectively target alloreactive effector T cells while sparing CD4+Foxp3+ regulatory T cells
(Tregs) to promote operational tolerance. Various approaches, notably the one based on
monoclonal antibodies or fusion proteins directed against the TCR/CD3 complex, TCR
coreceptors, or costimulatory molecules, have been proposed to reduce the alloreactive
T cell pool, which is an essential prerequisite to create a therapeutic window allowing
Tregs to induce and maintain allograft tolerance. In this mini review, we focus on the
differential sensitivity of Tregs and effector T cells to the depleting and inhibitory effect
of these immunotherapies, with a particular emphasis on CD3-specific antibodies that
beyond their immunosuppressive effect, also express potent tolerogenic capacities.
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Introduction
The clinical success of transplantation depends on a life-long use of immunosuppressive drugs
that depress the immune system in a global manner. These non-specific therapies significantly
reduced the incidence of acute rejection but the benefit in terms of chronic rejection or long-
term graft survival is uncertain. Indeed, the induction of a permanent immunosuppressive state,
which may be excessive in some patients, is associated with significant toxicity and morbidity with
increased incidence of cancer, opportunistic infections, and cardiovascular diseases. Therefore,
alternative approaches have been developed with the objective of targeting the unwanted immune
responses to the transplanted organ while sparing the beneficial functions of the immune system,
i.e., inducing operational tolerance. Strategies include the use of monoclonal antibodies (Abs) or
fusion proteins that block T cell activation, the infusion of donor antigens (DST), the induction of
hematopoietic chimerism (bone marrow transplantation), the use of immunomodulatory cytokines
or cell therapy (dendritic cells, regulatory T cells). These approaches utilize various mechanisms
of peripheral tolerance such as deletion, activation-induced cell death (AICD, apoptosis), anergy,
immune deviation, and/or induction of regulatory T cells (Tregs).
When looking at the data more closely, notably the one gained from studies using monoclonal
antibodies or fusion proteins, we can observe that most treatments differentially affect T cell
populations. In particular, activated effector T cells and CD4+Foxp3+ Tregs react differently to
the inhibitory or depleting effect of these biological agents. This is of importance as induction of
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transplant tolerance across full MHC histocompatibility barriers
is thought to require the presence of Foxp3+ Tregs as well as the
physical elimination of effector T cells. In this mini review, we will
discuss the differential sensitivity of T cell subsets to immunoint-
ervention with a particular focus on CD3 antibody-based therapy
in transplantation.
Differential Sensitivity of Effector and
Regulatory T Cells to Immunotherapy
Alloreactive T cells are present in naive recipients and are thus able
to recognize alloantigens and mount efficient immune responses
against the transplanted organ (1). Therefore, depletion or inhi-
bition of these alloreactive T cells is necessary to promote graft
survival (2). However, there is compelling data derived from
experimental models suggesting that this step is not sufficient
per se to induce peripheral tolerance and must be implemented
with mechanisms that maintain effective Treg function to control
both remaining alloreactive T cells and new thymic emigrants
(3). Therapeutic approaches should combine these two capacities
to induce permanent allograft acceptance and antigen-specific
tolerance.
In most experimental models, the success of therapeutic strate-
gies is associated with the fact they target effector T cells while
preserving CD4+Foxp3+ Tregs from deletion or functional inhi-
bition (Table 1). Indeed, reports both inmice and humans showed
that Foxp3+ Tregs are relatively spared from the lymphodepleting
effect of anti-thymocyte globulin (ATG) (4–11). ATG treatment
increased the frequency and the functional activity of Tregs and,
in some models, de novo generation of antigen-specific Tregs
has been demonstrated (12). Similarly, Treg number and activity
were not significantly affected by treatment with anti-lymphocyte
serum (ALS) (13).
In the same vein, short course of non-depleting CD4 and CD8
Abs (combined with CD40L Abs in someMHC-mismatched con-
ditions) efficiently promoted tolerance by inhibiting alloreative
T cells while promoting regulatory mechanisms (30). The use
TABLE 1 | Treg resistance to inhibition/depletion mediated by biological
agents in transplantation.
Strategies Transplanted organs Reference
ATG Skin (4, 5, 8–11)
Kidney
GVHD
Pancreatic islets
ALS Skin (14)
Non-depleting CD4 Abs Skin (15–18)
Heart
CD40L Abs Skin (16, 19–22)
Pancreatic islets
GVHD
CD28 Fab0 fragment Heart (23–25)
Kidney
Agonist IL-2/Fc+ antagonist IL-15/Fc Heart (26)
CD3 Abs Pancreatic islets (27–29)
Heart
of transgenic models revealed that non-depleting CD4 Abs leave
intact the proliferation of allospecific Tregs while abrogating the
expansion of allospecific effector T cells in vitro and in vivo (15,
16). Natural and induced CD4+Foxp3+ Tregs play crucial role
in inducing andmaintaining transplant tolerance throughmecha-
nisms of “linked suppression” and “infectious tolerance” (17, 30–
34). This occurs when a Foxp3+ Treg and a Foxp3  conventional
T cell recognize their respective alloantigens presented by the
same APC, thereby inducing a tolerizing signal within the con-
ventional T cells which acquire regulatory properties instead of
differentiating into alloreactive effector T cells. These “secondary”
Tregs can propagate the tolerance state by inducing “tertiary”
Tregs. The infectious nature of the process and the critical role
of CD4+Foxp3+ Tregs have been confirmed in a B6.Foxp3hCD2
transgenic mouse model (18). Importantly, the continuous pres-
ence of the alloantigens is required to ensure dominance by Tregs,
which accumulate in tolerated grafts where they efficiently control
alloreactive effectors (18, 35). Immunoregulatory cytokines also
contribute to CD4/CD8 Ab-induced tolerance, notably TGF-β,
which has been detected in tolerated grafts and can promote the
de novo generation of Foxp3+ Tregs (35–37).
Costimulatory blockade is another well-established strategy
that targetsmature peripheral T cells andmanipulates the immune
system in a manner that favors Treg development and abrogates
alloreactive responses (16, 19–21). It has been reproducibly shown
that administration of the fusion protein CTLA-4Ig and/or anti-
bodies to CD40L (CD154), BTLA, ICOS, OX-40, or CD28 effi-
ciently inhibits allogeneic effector T cell activation and expansion
(38). Combined with each other, with DST or immunosuppressive
drugs such as rapamycin, these biological agents induce long-term
acceptance of allogeneic organs and tissues in mice and non-
human primates (23, 24, 39–43). Interestingly, besides promot-
ing T cell unresponsiveness, some of these agents also induce T
cell apoptosis, which is partial and transient yet mandatory for
tolerance induction (40, 44–47). This is well illustrated by the
fact that recipient mice transgenic for the anti-apoptotic molecule
Bcl-xL are refractory to the therapeutic effect of CTLA-4Ig and
CD40L Abs and thereby reject skin or heart allografts (40, 44).
Importantly, several reports show that alloreactive effector T cells
are the primary targets of these therapeutic agents. For instance,
in a major MHC-mismatched skin graft model, combination of
CD40L Ab to DST promoted transplant tolerance through the
selective depletion of alloantigen-specific CD8+ T cells (47).
Another study revealed that CD40L Ab can fix complement
through its Fc fragment and mediates selective depletion of acti-
vated T cells, which, in association with rapamycin, induce long-
term graft survival (46). The use of CD40L F(ab0)2 fragments or
C3- and Fc receptor-deficient recipients completely abrogated the
therapeutic effect. Clonal deletion was illustrated by the disap-
pearance of effector T cells expressing specific TCR Vβ families
after treatment with CD40L Ab, CTLA-4Ig, and rapamycin (48).
Regulatory T cells resist the inhibitory/depleting effect of cos-
timulation blockade and they play a crucial role in the develop-
ment and the maintenance of transplant tolerance (38). Indeed,
their deletion abrogates tolerance and leads to graft rejection (22,
49). Expansion of thymus-derived Tregs as well as de novo genera-
tion of Tregs have been reported and infectious tolerance has been
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proposed as a keymechanisms allowing long-term allograft accep-
tance (30, 50). This positive effect onTregs is particularly observed
when rapamycin is combined to costimulatory blockade, which
is not the case when calcineurin inhibitors (CNIs: cyclosporine
A, tacrolimus) are used (20, 48, 51). It has been suggested that
CNIs have a detrimental effect onCD4+Foxp3+ Treg homeostasis
as they block NFAT activation and IL-2 production in contrast
to rapamycin which promotes Treg function and expansion (52–
55). Using endoscopic confocalmicroscopy and color-codedT cell
subsets, Fan et al. showed that the number of Tregs detectedwithin
the allografts and peripheral blood of mice treated with CD40L
Abs and rapamycin was similar to that of untreated recipients
but the number of effector T cells was drastically reduced after
treatment (20). In a graft-versus-host disease (GVHD) model,
CTLA-4Ig/CD40L Ab treatment prevented the expansion of host-
reactive donor T cells but promoted proliferation of Foxp3+
Tregs (22). Similar features were observed in vitro (21). In the
same vein, recent studies in non-human primates showed that
treatment with selective CD28 antagonists did not reduce Foxp3+
Treg number after transplantation and favored their accumulation
within the graft (23, 24). Interestingly, selective CD28 blockade
prevented formation of the immune synapse between alloreative
effector T cells and APC by inhibiting the TCR Stop signal while it
increased Treg contact time with APC and induced calciummobi-
lization which translated into enhanced Treg suppressive activity
(25). Such effects were not reported for CD80/86 antagonists.
As CD28-B7 interaction is mandatory for Treg development and
homeostasis, these results together with the data from the phase
III BENEFIT study, reporting an increased occurrence of acute
graft rejection episode and lymphoproliferative disorders in renal
transplant patients treated with belatacept, have raised concerns
about the negative impact of CD28-B7 blockade on regulatory
mechanisms and graft survival (56–58).
Preservation of Tregs homeostasis and function has been
demonstrated in other tolerance-promoting protocols. Tregs were
resistant to the lytic effect of a regimen combining rapamycin,
agonist IL-2/Fc, and antagonist mutant IL-15/Fc fusion proteins
that depleted activated effector T cells through apoptosis and
antibody-dependent pathway and promoted long-term engraft-
ment of allogeneic skins and pancreatic islets (26). However, appli-
cation of this treatment in non-human primates only permitted
a modest prolongation of cardiac allograft survival and did not
reduce the pool of effector or memory CD8+ T cells although
Tregs were found in increased numbers in the blood of treated
animals (59).
A Distinct Effect of CD3-Specific
Antibodies on Tregs and Effector T Cells
CD3-specific monoclonal Abs act through distinct mechanisms
that are not mutually exclusive (60). The antibodies transiently
deplete T cells although they display no or little complement-
dependent and antibody-dependent cellular cytotoxicity. Mech-
anism of redirected cell lysis due to the ability to crosslink CD3
molecules expressed by two different cells (cytotoxic CD8+ T cells
on one side and other target T cells on the other side) has been
demonstrated (61). However, T cell depletion mostly results from
AICD. Indeed, through its F(ab0)2 portion, CD3 Ab can not only
induce antigenic modulation (i.e., internalization or shedding of
the TCR/CD3 complex) but also can transduce signals into T cells,
which activate them and promotes their apoptosis (AICD) or
anergy. Importantly, non-FcR binding human or mouse CD3 Abs
are not passive blocker of TCRs, they can deliver partial TCR
signaling and retain their full therapeutic properties without the
toxicity associated with the parental CD3 Ab (62–65). This has
been the rationale of using humanized CD3 antibodies in the
clinic in type 1 diabetes patients (66–68).
We and other accumulated evidence showing that CD3 Abs
preferentially target and deplete activated effector T cells while
preserving CD4+Foxp3+ Tregs. This finding was initially sug-
gested by indirect observations in autoimmunity showing that
CD3 Abs exert their tolerogenic capacities only when applied at
the time of ongoing autoreactive responses or established disease
(60, 62, 69). These data highlighted the importance of the immune
activation status toward the relevant antigen(s) at the time of
treatment. We obtained the same results when translating CD3
Ab therapy to the transplantation field. In experimental models
of fully mismatched pancreatic islets or cardiac allografts, low-
dose treatment of recipient mice at the time of transplantation
prolonged graft survival but rejection occurred systematically
(27, 28). By contrast, when postponing CD3 Ab administration
after transplantation, in a defined therapeutic window, long-term
survival and immune tolerance were observed. This therapeutic
window corresponded to the time of effector T cell priming to the
alloantigens characterized by the occurrence of anti-donor T cell
responses and infiltration of allografts by significant number of
alloreative T cells (27, 28).
Several experimental data argue for the preferential elimina-
tion of activated effector T cells by CD3 antibodies. First, using
a transfer model where OVA-specific OT-I CD8+ T cells were
primed in vivo by SIINFEKL(OVA)-loaded dendritic cells, we
showed that only highly dividingOT-I cells entered apoptosis after
CD3 Ab administration applied 6 days after cell infusion. Resting
endogenous CD8+ T cells were not affected by the treatment (27).
Second, in a murine model of GVHD, injection of CD3 F(ab0)2
fragments selectively depleted activated donor T cells that under-
went cell division upon recipient antigens recognition (70). Third,
using another non-Fc receptor bindingCD3Ab (145-2C11-IgG3),
Penaranda et al. showed that adoptively transferred effector Th1
cells were much more sensitive to the depleting effect of CD3 Abs
than endogenous naïve T cells (71). Fourth, in vitro experiments
also showed that non-Fc receptor binding humanized CD3 Abs
displayed an increased ability to deplete activated human T cells
through AICD (63, 72).
In contrast to effector T cells, Foxp3+ Tregs appear resistant to
CD3Ab-mediated cell death. Indeed, in terms of absolute number,
the decrease in Foxp3+ T cells is always much less pronounced
than that observed for conventional Foxp3  T cells and, in some
situations, is not altered at all (27, 71, 73, 74). Consequently,
the frequency of Tregs significantly increases in peripheral blood
and secondary lymphoid organs after CD3 Ab treatment. Similar
results were reported for CD4+CD25+CD62L+ T cells (75). In
most reports, no evidence of conversion of conventional T cells
into Tregs as well as significant expansion of natural Tregs were
reported except in a recent article by Valle et al. showing an
increase in Treg count in the blood of treated mice resulting from
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in vivo proliferation (73). The reduced sensitivity of CD4+Foxp3+
Tregs to CD3 Abs was illustrated at the molecular level by a tran-
scriptome analysis showing that gene expression profile (related
to the TCR signaling pathway) of Tregs was much less impacted
than the one of CD4+Foxp3  T cells after in vivo treatment with
CD3 Abs (73). All these data concur to show that Tregs resist CD3
Ab-induced AICD.
This feature of Tregs is crucial for CD3 Ab-induced transplant
tolerance. Both in the pancreatic islet and the cardiac allograft
models, we observed that the proportion of CD4+ and CD8+
T cells significantly decreased at the periphery and within the
grafted organs after administration of CD3 Ab F(ab0)2 fragments
(27, 28, 76). However, depletion of Foxp3+ Tregs was very limited
as compared to that of CD8+ T cells or CD4+Foxp3  T cells
(27, 28). Consequently, peripheral and intragraft Treg propor-
tion increased after CD3 Ab therapy (27–29, 76). Foxp3+ Tregs
isolated from CD3 Ab-treated tolerant mice and adoptively trans-
ferred into a RAG /  recipients were able to prevent graft rejec-
tionmediated by naïve spleen cells toward islet allografts from the
same donor but not from a third-party donor, thereby indicat-
ing that these Tregs play a key role in sustained antigen-specific
transplant tolerance over long term (27).
Mechanisms of Resistance
All these data concur to show that Foxp3+ Tregs are less sensitive
than effector T cells to the apoptotic or inhibitory effect of thera-
peutic antibodies. The mechanisms underlying this resistance are
not completely elucidated. In the context of ALS treatment, it has
been proposed that this resistance to cell death is dependent on
the costimulatory molecule OX-40 as well as the anti-apoptotic
molecule Bcl-xL that was detected at higher levels in Tregs than
in conventional T cells (13, 14). Another mechanism that may
contribute to Treg resistance to apoptosis is related to studies sug-
gesting that they express lower levels of FasLigand (CD95L) upon
stimulation as compared to conventional Foxp3  T cells (77).
Abrogation of Foxp3 expression (in Scurfy mice) rescues FasL
expression at the level comparable to those of conventional T cells,
suggesting that Foxp3 controls, at least in part, the expression of
FasL and AICD. Accordingly, naïve Tregs has been shown to be
more resistant to Fas-induced cell death than conventional T cells
(78, 79).
In the context of CD3 antibody therapy, the differential effect
of the antibody on effector versus regulatory T cells appears
paradoxical as the CD3 molecular complex is expressed on all
T cells. The reasons explaining this differential effect are still not
elucidated. However, recent studies suggested that both human
and mouse Tregs harbor less CD3 molecules (comprising the
CD3" chain, which is that target of the therapeutic antibodies) on
their surface than do CD4+Foxp3  T cells and that this variable
expression level correlatedwith different susceptibility toCD3Ab-
mediated cell death (73, 80). In addition, it has been suggested that
Tregs (CD4+CD25+) possess distinct isoforms of the CD3epsilon
chain characterized by an undegraded N-terminal sequence of
negatively charged amino acid residues that is associated with
a higher activation threshold (80). A diminished expression of
signaling molecules downstream of the TCR/CD3 complex has
also been reported in Tregs (CD3ζ, ZAP-70, LcK, Vav, and PI3K
p110α) as well as a reduced signaling after TCR engagement in
response to CD3 antibodies (phospho-ZAP-70, -Akt, -Erk1/2, -
PLCγ1) as compared to conventional T cells (CD4+CD25 ) (80,
81). Lastly, the fact that Foxp3+ Tregs may express lower levels of
FasL upon stimulation than Foxp3  T cells may account for their
resistance to the depleting effect of CD3 antibodies that is at least
partially mediated by the Fas/FasL pathway (60, 77).
Concluding Remarks
Several potentially important biological agents have been used to
prevent transplant rejection with the aim of inducing transplant
tolerance. The intrinsic resistance of Tregs to the depleting effect
of these therapeutic tools, which preferentially target effector
alloreative T cells, encourages clinical translation of these strate-
gies. Unfortunately, so far, these tolerance-promoting protocols
are often disappointing when applied to human transplantation
(82). To move faster and to achieve successful translation to the
clinical arena in a not too distant future, clinicians and researchers
need to build on the drugs currently in clinical development to
design new tolerogenic protocols. The challenge is to use these
biological tools in a defined therapeutic window to reveal their
tolerogenic capacities (i.e., deleting effector/memory alloreactive
T cells while harnessing Tregs) in order to minimize/withdraw
immunosuppressive drugs without increased risks of acute rejec-
tion but in a manner that positively impact on long-term graft
survival through the induction of operational tolerance. In that sit-
uation, CD3-specific Abs may represent one promising approach
as they afford long-term therapeutic effect following a short-term
and low-dose administration. Finally, these features are further
emphasized by the growing interest on Treg cell therapy in trans-
plantation (83, 84). Indeed, the use of in vitro expanded Tregs
requires the selection of therapeutic agents that enhance Treg
action to enable efficacy of the combined therapy and application
to clinical transplantation (85, 86).
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